• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NantHealth Reports 2021 Third Quarter Financial Results

    11/4/21 4:06:00 PM ET
    $NH
    EDP Services
    Technology
    Get the next $NH alert in real time by email
    • Q3 2021 Financial Highlights:
      • Total net revenue was $14.4 million
      • Gross margin was 52%
      • Cash of $45.5 million at September 30, 2021
    • Operational Highlights:
      • Signed and preparing to launch first Eviti Connect program for autoimmune disease
      • Achieved utilization management licensure/certification in six states enabling expansion of Eviti Connect to include fully delegated services
      • In October, signed multi-year NaviNet Open agreement with third party administration service provider with potential to deploy provider portal capabilities to multiple new self-insured health plans
      • Also in October, signed agreement with Care Continuity allowing parties to partner on product offerings that improve care logistics for complex, high risk and chronic diseases for health plan and provider customers
      • Enhanced leadership team with addition of experienced senior-level executives in sales, strategy and human resources

     

    NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today reported financial results for its third quarter ended September 30, 2021.

    "Expansion of our Eviti Connect decision support solution to additional diseases states (beyond oncology) has been a major focus for us this year," said Ron Louks, Chief Operating Officer, NantHealth. "With that in mind, I am pleased to report that, during the third quarter, we signed and are preparing to launch the very first Eviti Connect autoimmune disease program with a key customer and interest in this new offering is strong. This was a significant accomplishment and, when coupled with investments we are making in our network monitoring and management service suite (OpenNMS®) and data capabilities (Quadris™), we believe these advancements lay the foundation for substantial new growth opportunities for our business.

    "On the financial front, net revenue for the 2021 third quarter was lower than the previous quarter, primarily due to timing differences between the expiration of certain contracts and the initiation of others. For the 2021 fourth quarter, we expect net revenue to return closer to our average run rate for this year.

    "Also, as announced today in a dedicated press release, we added three senior executives to head our sales, strategy and human resource functions. All are accomplished and experienced leaders, and we look forward to the benefit of their insights as we begin the next stage of our growth."

    Software and Services Highlights:

    • Clinical Decision Support (Eviti®):
      • Continued expansion of services provided through a key Eviti channel partner, with the addition of two new health plans and expect further growth in the fourth quarter with the addition of a large, multi-state customer-owned health insurer
      • Signed agreement with Care Continuity, Inc., a leader in network integrity and care navigation, to partner on product offerings that improve care logistics management for complex, high risk and chronic diseases, with an initial focus on extending care pathways for Eviti Connect customers and their members (with NaviNet care pathway opportunities to follow)
      • Dr. Tiffany Avery, NantHealth Chief Medical Officer, was selected to present continuing education session on advancing equity in cancer care at the Oncology Clinical Pathways Congress. The virtual session took place October 1
      • Launched Eviti Connect 8.6, which includes more robust savings and ROI visualizations for payer customers via expanded reporting that is enabled by our Quadris data analytics capabilities
    • Payer Engagement (NaviNet® and Population Health Management):
      • In October, signed a multi-year agreement with a new third party administrator that will use NaviNet Open to enhance the services it provides to self-insured health plan customers
      • Signed three-year renewal with a long-term partner and leading provider of drug authorizations, enabling electronic submission of prior authorization for any drug under any plan, including Medicare and Medicaid
      • Established a collaboration with Intraprise Systems to bring HIPAA One compliance management solutions to the NaviNet provider network, helping providers meet HIPAA compliance requirements and protect patient data
      • Launched the new NantHealth Help Center, an innovative platform that provides users with easy access to help and training content, online channels to contact support, and tools to view in progress and resolved support requests
      • Introduced new Authorization Submission APIs that allow providers to automate and streamline prior authorization requests to connected NaviNet payer customers
    • Network Monitoring and Management (The OpenNMS Group, Inc.):
      • Renewed agreements with 12 key customers and expanded services with one of the nation's largest telecom providers (an existing account), reaffirming the value OpenNMS provides its customers
      • Continued development and preparation for fourth quarter launch of zero-touch appliances, simplifying the deployment of distributed monitoring capabilities at scale

    Business and Financial Highlights

    For the 2021 third quarter:

    • Total net revenue was $14.4 million compared with $18.8 million in Q3 of 2020.
    • Gross profit was $7.5 million, or 52% of total net revenue, compared with $11.2 million, or 60% of total net revenue, for the prior-year period.
    • Selling, general and administrative (SG&A) expenses increased to $13.0 million from $12.4 million in the 2020 third quarter.
    • Research and development (R&D) expenses decreased to $4.6 million from $4.7 million.
    • Net loss from continuing operations, net of tax, was $10.8 million, or $0.09 per share, compared with $11.0 million, or $0.10 per share, in the 2020 third quarter.
    • Non-GAAP net loss from continuing operations was $11.5 million, or $0.10 per share, compared with $7.2 million, or $0.07 per share, for the third quarter of 2020.
    • At September 30, 2021, cash and cash equivalents totaled $45.5 million.

    Conference Call Information and Forward-Looking Statements

    Later today, the Company will host a conference call at 1:30 p.m. PT (4:30 p.m. ET) to review its results of operations for the third quarter ended September 30, 2021. The conference call will be available to interested parties by dialing 800-584-1507 from the U.S. or Canada, or 212-231-2902 from international locations. The call will be broadcast via the Internet at www.nanthealth.com. Listeners are encouraged to visit the website at least 10 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software. A playback of the call will be archived and accessible on the same website for at least three months.

    Discussion during the conference call may include forward-looking statements regarding topics such as the Company's financial status and performance, regulatory and operational developments, and other comments the Company may make about its future plans or prospects in response to questions from participants on the conference call.

    Use of Non-GAAP Financial Measures

    This news release contains references to Non-GAAP financial measures, including adjusted net loss and adjusted net loss per share, which are financial measures that are not prepared in conformity with United States generally accepted accounting principles (U.S. GAAP). The Company's management believes that the presentation of Non-GAAP financial measures provides useful supplementary information regarding operational performance, because it enhances an investor's overall understanding of the financial results for the Company's core business. Additionally, it provides a basis for the comparison of the financial results for the Company's core business between current, past and future periods. Other companies may define these measures in different ways. Non-GAAP financial measures should be considered only as a supplement to, and not as a substitute for or as a superior measure to, financial measures prepared in accordance with U.S. GAAP. Non-GAAP per share numbers are calculated based on one class of common stock and do not incorporate the effects, if any, of using the two-class method.

    About NantHealth, Inc.

    NantHealth, a member of the NantWorks ecosystem of companies, provides enterprise solutions that help businesses transform complex data into actionable insights. By offering efficient ways to move, interpret and visualize complex and highly sensitive information, NantHealth enables customers in healthcare, life sciences, logistics, telecommunications and other industries to automate, understand and act on data while keeping it secure and scalable. NantHealth's product portfolio comprises the latest technology in payer/provider collaboration platforms for real-time coverage decision support (Eviti and NaviNet), and data solutions that provide multi-data analysis, reporting and professional services offerings (Quadris). The OpenNMS Group, Inc., a NantHealth subsidiary, helps businesses monitor and manage network health and performance. For more information, visit nanthealth.com, follow us on Twitter, Facebook, LinkedIn and YouTube and subscribe to our blog.

    This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; our ability to grow the market for our software and data solutions; successfully enhancing our software and data solutions to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to integrate The OpenNMS Group, Inc. into our operations; our use and distribution of open source software; our ability to obtain necessary regulatory approvals, certifications and licenses; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.

    NantHealth, Inc.

    Consolidated Balance Sheets

    (Dollars in thousands)

     

    September 30,

    2021

     

    December 31,

    2020

     

    (Unaudited)

     

     

    Assets

     

     

     

    Current assets

     

     

     

    Cash and cash equivalents

    $

    45,513

     

     

     

    $

    22,787

     

     

    Accounts receivable, net

    4,504

     

     

     

    3,273

     

     

    Related party receivables, net

    1,516

     

     

     

    1,031

     

     

    Prepaid expenses and other current assets

    5,262

     

     

     

    3,504

     

     

    Total current assets

    56,795

     

     

     

    30,595

     

     

    Property, plant, and equipment, net

    12,875

     

     

     

    13,102

     

     

    Goodwill

    98,333

     

     

     

    98,333

     

     

    Intangible assets, net

    41,272

     

     

     

    47,969

     

     

    Related party receivable, net of current

    —

     

     

     

    823

     

     

    Operating lease right-of-use assets

    6,497

     

     

     

    7,539

     

     

    Other assets

    1,596

     

     

     

    1,927

     

     

    Total assets

    $

    217,368

     

     

     

    $

    200,288

     

     

     

     

     

     

    Liabilities and Stockholders' Equity

     

     

     

    Current liabilities

     

     

     

    Accounts payable

    $

    2,069

     

     

     

    $

    5,122

     

     

    Accrued and other current liabilities

    14,380

     

     

     

    13,975

     

     

    Deferred revenue

    1,938

     

     

     

    1,166

     

     

    Related party payables, net

    5,136

     

     

     

    4,238

     

     

    Notes payable

    1,557

     

     

     

    268

     

     

    Related party convertible note, net

    4,995

     

     

     

    9,411

     

     

    Convertible notes, net

    4,488

     

     

     

    90,578

     

     

    Total current liabilities

    34,563

     

     

     

    124,758

     

     

    Deferred revenue, net of current

    1,682

     

     

     

    393

     

     

    Related party liabilities

    36,465

     

     

     

    31,091

     

     

    Related party promissory note

    112,666

     

     

     

    112,666

     

     

    Related party convertible note, net

    62,251

     

     

     

    —

     

     

    Convertible notes, net

    74,583

     

     

     

    —

     

     

    Deferred income taxes, net

    1,673

     

     

     

    1,853

     

     

    Operating lease liabilities

    6,878

     

     

     

    8,170

     

     

    Other liabilities

    33,398

     

     

     

    32,757

     

     

    Total liabilities

    364,159

     

     

     

    311,688

     

     

    Commitments and Contingencies (Note 14)

     

     

     

     

     

     

     

    Stockholders' deficit

     

     

     

    Common stock, $0.0001 par value per share, 750,000,000 shares authorized; 115,307,744 and 111,284,733 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively

    12

     

     

     

    11

     

     

    Additional paid-in capital

    889,620

     

     

     

    891,583

     

     

    Accumulated deficit

    (1,036,192

    )

     

     

    (1,003,210

    )

     

    Accumulated other comprehensive loss

    (231

    )

     

     

    (168

    )

     

    Total NantHealth stockholders' deficit

    (146,791

    )

     

     

    (111,784

    )

     

    Noncontrolling interests

    —

     

     

     

    384

     

     

    Total stockholders' deficit

    (146,791

    )

     

     

    (111,400

    )

     

    Total liabilities and stockholders' deficit

    $

    217,368

     

     

     

    $

    200,288

     

     

    NantHealth, Inc.

    Consolidated Statements of Operations

    (Dollars in thousands, except per share amounts)

    (Unaudited)

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

    2021

     

     

    2020

     

     

    2021

     

     

    2020

     

    Revenue

     

     

     

     

     

     

     

    Software-as-a-service related

    $

    13,879

     

     

     

    $

    18,355

     

     

     

    $

    45,140

     

     

     

    $

    53,997

     

     

    Maintenance

    406

     

     

     

    299

     

     

     

    1,201

     

     

     

    299

     

     

    Professional services

    57

     

     

     

    62

     

     

     

    257

     

     

     

    62

     

     

    Total software-related revenue

    14,342

     

     

     

    18,716

     

     

     

    46,598

     

     

     

    54,358

     

     

    Other

    17

     

     

     

    49

     

     

     

    20

     

     

     

    172

     

     

    Total net revenue

    14,359

     

     

     

    18,765

     

     

     

    46,618

     

     

     

    54,530

     

     

     

     

     

     

     

     

     

     

    Cost of Revenue:

     

     

     

     

     

     

     

    Software-as-a-service related

    5,244

     

     

     

    5,935

     

     

     

    16,223

     

     

     

    17,552

     

     

    Maintenance

    298

     

     

     

    131

     

     

     

    775

     

     

     

    131

     

     

    Professional services

    6

     

     

     

    15

     

     

     

    13

     

     

     

    15

     

     

    Amortization of developed technologies

    1,247

     

     

     

    1,222

     

     

     

    3,741

     

     

     

    3,508

     

     

    Total software-related cost of revenue

    6,795

     

     

     

    7,303

     

     

     

    20,752

     

     

     

    21,206

     

     

    Other

    34

     

     

     

    216

     

     

     

    127

     

     

     

    827

     

     

    Total cost of revenue

    6,829

     

     

     

    7,519

     

     

     

    20,879

     

     

     

    22,033

     

     

     

     

     

     

     

     

     

     

    Gross Profit

    7,530

     

     

     

    11,246

     

     

     

    25,739

     

     

     

    32,497

     

     

     

     

     

     

     

     

     

     

    Operating Expenses

     

     

     

     

     

     

     

    Selling, general and administrative

    12,969

     

     

     

    12,442

     

     

     

    37,309

     

     

     

    36,864

     

     

    Research and development

    4,648

     

     

     

    4,681

     

     

     

    14,510

     

     

     

    12,446

     

     

    Amortization of acquisition-related assets

    985

     

     

     

    958

     

     

     

    2,956

     

     

     

    2,691

     

     

    Total operating expenses

    18,602

     

     

     

    18,081

     

     

     

    54,775

     

     

     

    52,001

     

     

     

     

     

     

     

     

     

     

    Loss from operations

    (11,072

    )

     

     

    (6,835

    )

     

     

    (29,036

    )

     

     

    (19,504

    )

     

    Interest expense, net

    (3,572

    )

     

     

    (4,861

    )

     

     

    (10,943

    )

     

     

    (14,291

    )

     

    Other income (expense), net

    3,759

     

     

     

    747

     

     

     

    (1,862

    )

     

     

    (2,550

    )

     

    Loss from related party equity method investment

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (31,702

    )

     

    Loss from continuing operations before income taxes

    (10,885

    )

     

     

    (10,949

    )

     

     

    (41,841

    )

     

     

    (68,047

    )

     

    Provision for income taxes

    23

     

     

     

    77

     

     

     

    21

     

     

     

    174

     

     

    Net loss from continuing operations

    (10,908

    )

     

     

    (11,026

    )

     

     

    (41,862

    )

     

     

    (68,221

    )

     

    Income (loss) from discontinued operations, net of tax attributable to NantHealth

    —

     

     

     

    (16

    )

     

     

    24

     

     

     

    31,955

     

     

    Net loss

    (10,908

    )

     

     

    (11,042

    )

     

     

    (41,838

    )

     

     

    (36,266

    )

     

    Net loss attributable to non-controlling interests

    (65

    )

     

     

    (42

    )

     

     

    (284

    )

     

     

    (42

    )

     

    Net loss attributable to NantHealth

    $

    (10,843

    )

     

     

    $

    (11,000

    )

     

     

    $

    (41,554

    )

     

     

    $

    (36,224

    )

     

     

     

     

     

     

     

     

     

    Basic and diluted net (loss) income per share attributable to NantHealth:

     

     

     

     

     

     

     

    Continuing operations - common stock

    $

    (0.09

    )

     

     

    $

    (0.10

    )

     

     

    $

    (0.37

    )

     

     

    $

    (0.62

    )

     

    Discontinued operations - common stock

    $

    —

     

     

     

    $

    —

     

     

     

    $

    —

     

     

     

    $

    0.29

     

     

    Total net loss per share - common stock

    $

    (0.09

    )

     

     

    $

    (0.10

    )

     

     

    $

    (0.37

    )

     

     

    $

    (0.33

    )

     

     

     

     

     

     

     

     

     

    Weighted average shares outstanding

     

     

     

     

     

     

     

    Basic and diluted - common stock

    115,243,671

     

     

     

    110,929,357

     

     

     

    113,706,124

     

     

     

    110,859,611

     

     

    NantHealth, Inc.

    Non-GAAP Net Loss from Continuing Operations Attributable to NantHealth and

    Non-GAAP Net Loss Per Share from Continuing Operations Attributable to NantHealth

    (Dollars in thousands, except per share amounts)

    (Unaudited)

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

    2021

     

     

    2020

     

     

    2021

     

     

    2020

     

    Net loss from continuing operations attributable to NantHealth

    $

    (10,843

    )

     

     

    $

    (10,984

    )

     

     

    $

    (41,578

    )

     

     

    $

    (68,179

    )

     

    Adjustments to GAAP net loss from continuing operations attributable to NantHealth:

     

     

     

     

     

     

     

    Loss on Exchange and Prepayment of 2016 Notes

    —

     

     

     

    —

     

     

     

    742

     

     

     

    —

     

     

    Loss from related party equity method investment

    —

     

     

     

    —

     

     

     

    —

     

     

     

    31,702

     

     

    Stock-based compensation expense from continuing operations

    799

     

     

     

    633

     

     

     

    2,533

     

     

     

    1,761

     

     

    Change in fair value of derivatives liability

    —

     

     

     

    (56

    )

     

     

    (4

    )

     

     

    7

     

     

    Change in fair value of Bookings Commitment

    (3,670

    )

     

     

    (657

    )

     

     

    1,133

     

     

     

    3,070

     

     

    Noncash interest expense related to convertible notes

    58

     

     

     

    1,644

     

     

     

    568

     

     

     

    4,779

     

     

    Intangible amortization from continuing operations

    2,222

     

     

     

    2,165

     

     

     

    6,646

     

     

     

    6,184

     

     

    Securities litigation costs

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (103

    )

     

    Tax benefit (provision) resulting from certain noncash tax items

    (17

    )

     

     

    20

     

     

     

    (105

    )

     

     

    (16

    )

     

    Total adjustments to GAAP net loss from continuing operations attributable to NantHealth

    (608

    )

     

     

    3,749

     

     

     

    11,513

     

     

     

    47,384

     

     

    Net loss from continuing operations attributable to NantHealth - Non-GAAP

    $

    (11,451

    )

     

     

    $

    (7,235

    )

     

     

    $

    (30,065

    )

     

     

    $

    (20,795

    )

     

     

     

     

     

     

     

     

     

    Weighted average basis common shares outstanding

    115,243,671

     

     

     

    110,929,357

     

     

     

    113,706,124

     

     

     

    110,859,611

     

     

     

     

     

     

     

     

     

     

    Net loss per common share from continuing operations attributable to NantHealth - Non-GAAP

    $

    (0.10

    )

     

     

    $

    (0.07

    )

     

     

    $

    (0.26

    )

     

     

    $

    (0.19

    )

     

    Reconciliation of Net Loss per Common Share from Continuing Operations Attributable to NantHealth

    to Net Loss per Common Share from Continuing Operations Attributable to NantHealth - Non-GAAP

    (Unaudited)

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

    2021

     

     

    2020

     

     

    2021

     

     

    2020

     

    Net loss per common share from continuing operations attributable to NantHealth

    $

    (0.09

    )

     

     

    $

    (0.10

    )

     

     

    $

    (0.37

    )

     

     

    $

    (0.62

    )

     

    Adjustments to GAAP net loss per common share from continuing operations attributable to NantHealth:

     

     

     

     

     

     

     

    Loss on Exchange and Prepayment of 2016 Notes

    —

     

     

     

    —

     

     

     

    0.01

     

     

     

    —

     

     

    Loss from related party equity method investment

    —

     

     

     

    —

     

     

     

    —

     

     

     

    0.28

     

     

    Stock-based compensation expense from continuing operations

    0.01

     

     

     

    0.01

     

     

     

    0.03

     

     

     

    0.02

     

     

    Change in fair value of derivatives liability

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

    Change in fair value of Bookings Commitment

    (0.04

    )

     

     

    (0.01

    )

     

     

    0.01

     

     

     

    0.03

     

     

    Noncash interest expense related to convertible notes

    —

     

     

     

    0.01

     

     

     

    —

     

     

     

    0.04

     

     

    Intangible amortization from continuing operations

    0.02

     

     

     

    0.02

     

     

     

    0.06

     

     

     

    0.06

     

     

    Securities litigation costs

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

    Tax benefit (provision) resulting from certain noncash tax items

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

    Total adjustments to GAAP net loss per common share from continuing operations attributable to NantHealth

    (0.01

    )

     

     

    0.03

     

     

     

    0.11

     

     

     

    0.43

     

     

    Net loss per common share from continuing operations attributable to NantHealth - Non-GAAP

    $

    (0.10

    )

     

     

    $

    (0.07

    )

     

     

    $

    (0.26

    )

     

     

    $

    (0.19

    )

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20211104006140/en/

    Get the next $NH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NH
    SEC Filings

    View All

    SEC Form 15-12G filed by NantHealth Inc.

    15-12G - NantHealth, Inc. (0001566469) (Filer)

    2/13/24 5:21:52 PM ET
    $NH
    EDP Services
    Technology

    NantHealth Inc. filed SEC Form 8-K: Leadership Update

    8-K - NantHealth, Inc. (0001566469) (Filer)

    2/8/24 5:29:21 PM ET
    $NH
    EDP Services
    Technology

    SEC Form EFFECT filed by NantHealth Inc.

    EFFECT - NantHealth, Inc. (0001566469) (Filer)

    1/30/24 12:15:09 AM ET
    $NH
    EDP Services
    Technology

    $NH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Naseem Rao Haris

    4 - NantHealth, Inc. (0001566469) (Issuer)

    9/19/23 5:43:17 PM ET
    $NH
    EDP Services
    Technology

    SEC Form 3: New insider Naseem Rao Haris claimed ownership of 3,846,154 shares

    3 - NantHealth, Inc. (0001566469) (Issuer)

    9/15/23 6:32:11 PM ET
    $NH
    EDP Services
    Technology

    SEC Form 3: New insider Summus Holdings Llc claimed ownership of 3,846,154 shares

    3 - NantHealth, Inc. (0001566469) (Issuer)

    9/15/23 6:27:53 PM ET
    $NH
    EDP Services
    Technology

    $NH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NantHealth's Eviti Connect Achieves HITRUST Risk-based, 2-year Certification to Further Mitigate Risk in Third-Party Privacy, Security and Compliance

    HITRUST Certification validates NantHealth's commitment to aligning with key regulations and protecting sensitive information NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions transforming complex data into actionable insights, today announced its Eviti Connect solution has earned Certified status for information security by HITRUST. HITRUST Risk-based, 2-year (r2) Certified status demonstrates that NantHealth's Eviti Connect solution has met key regulations and industry-defined requirements for managing risk. This achievement places NantHealth in an elite group of organizations worldwide that have earned this certification. "Organizations like ours are under c

    3/21/23 9:00:00 AM ET
    $NH
    EDP Services
    Technology

    NantHealth Announces $22.5 Million New Financing with Highbridge and Nant Capital

    NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced the entry into a credit agreement for a new senior secured term loan in an aggregate principal amount of $22.5 million. The company intends to use the proceeds to continue funding its existing businesses and for general corporate purposes. The Term Loan Facility was funded by two existing NantHealth investors: Highbridge Capital Management, LLC and Nant Capital, LLC. "The era of digital medicine and augmented intelligence has finally arrived. NantHealth has stood at the forefront of driving evidence based, low cost care to treat

    3/6/23 9:00:00 AM ET
    $NH
    EDP Services
    Technology

    OpenNMS releases OpenNMS Meridian 2023 with New Cloud-enabled Capabilities

    Meridian 2023 is a look into the future of network monitoring, centered around simplification The OpenNMS Group, Inc., a subsidiary of NantHealth, Inc. (NASDAQ:NH), today announced the release of OpenNMS Meridian 2023. With this major release, the fully open source Meridian product, which is the optimized and supported version of the OpenNMS platform curated by The OpenNMS Group, Inc. (OpenNMS) for production environments, now features cloud services, containerization benefits, and other advancements. "The cloud capabilities we're launching with Meridian 2023 bring us a huge step closer to our vision of a world where monitoring just happens," said David Hustace, President, Founderat OpenN

    2/22/23 9:00:00 AM ET
    $NH
    EDP Services
    Technology

    $NH
    Leadership Updates

    Live Leadership Updates

    View All

    NantHealth Expands, Strengthens Senior Management Team with Appointment of Three Key Executives

    Jerry Magin, Neil Carpenter, and Arlyn Small join leadership team to drive next-level company growth NantHealth, Inc. (NASDAQ:NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced the appointments of Jerry Magin as Senior Vice President of Global Sales and Marketing; Neil Carpenter as Senior Vice President of Strategy and Arlyn Small as Senior Vice President of Human Resources, to its executive leadership team. Jerry Magin has more than 25 years of industry experience building and scaling high-performing marketing, business development, sales and operational teams. In his role as Senior Vice President of Globa

    11/4/21 4:05:00 PM ET
    $NH
    EDP Services
    Technology

    NantHealth Appoints Dr. Tiffany Avery as Chief Medical Officer

    NantHealth, Inc. (NASDAQ:NH), a provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced the appointment of Tiffany Avery, MD, MPH, as Chief Medical Officer. In her new position, Dr. Avery will be responsible for providing clinical strategic direction and guiding the development and deployment of NantHealth's Eviti decision support platform and other innovative products and services. "Appointing Dr. Avery to our leadership team is an incredibly valuable addition to the organization, particularly as we expand into areas like population health and additional disease states for Eviti," said Ron Louks, Chief Operating Officer, NantH

    8/3/21 9:00:00 AM ET
    $NH
    EDP Services
    Technology

    $NH
    Financials

    Live finance-specific insights

    View All

    NantHealth Reports 2022 Third Quarter Financial Results

    Q3 2022 Financial and Operational Highlights: Total net revenue was $16.6 million Gross profit was $9.7 million, or 58% of total revenue The company's Eviti Connect platform earned full URAC accreditation for Health Utilization Management, through 2025 Maryland Physicians Care signed a two-year renewal agreement for Eviti Connect for Autoimmune Diseases Post quarter end: Secured 3-year contract extension with large national commercial insurer that provides coverage to more than two million Medicaid members across multiple states. Expanded contract now includes formulary redirection NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help busi

    11/3/22 4:05:00 PM ET
    $NH
    EDP Services
    Technology

    NantHealth to Report 2022 Third-Quarter Financial Results and Host Conference Call on Thursday, November 3

    NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced that it will report financial results for its 2022 third quarter on Thursday, November 3, 2022, after market close. NantHealth management will host a conference call that same day at 1:30 p.m. PT (4:30 p.m. ET) to review the company's performance. The conference call will be available to interested parties by dialing 800-942-2493 from the U.S. or Canada, or 212-231-2931 from international locations. The call will be broadcast via the Internet at www.nanthealth.com. About NantHealth, Inc. NantHealth, a member of the NantWorks ec

    10/31/22 4:50:00 PM ET
    $NH
    EDP Services
    Technology

    NantHealth Reports 2022 Second Quarter Financial Results

    Q2 2022 Financial and Operational Highlights: Total net revenue was $16.5 million Gross margin was 55% of total revenue NantHealth products won three industry awards, one from MedTech Breakthrough and two from Spring Digital Health NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today reported financial results for its second quarter ended June 30, 2022. "For the 2022 second quarter, we reported net revenue of $16.5 million, representing the third consecutive quarter of top-line growth," said Ron Louks, Chief Operating Officer, NantHealth. "We are pleased to note that our overall gro

    8/4/22 4:05:00 PM ET
    $NH
    EDP Services
    Technology

    $NH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by NantHealth Inc.

    SC 13D - NantHealth, Inc. (0001566469) (Subject)

    9/26/23 5:27:57 PM ET
    $NH
    EDP Services
    Technology

    SEC Form SC 13D filed by NantHealth Inc.

    SC 13D - NantHealth, Inc. (0001566469) (Subject)

    9/7/23 5:27:56 PM ET
    $NH
    EDP Services
    Technology